Research programme: wound healing therapy - TA TherapeuticsAlternative Names: Wound healing therapy research programme - TA Therapeutics
Latest Information Update: 12 Mar 2010
At a glance
- Originator Geron Corporation; TA Therapeutics
- Class Gene therapies; Small molecules
- Mechanism of Action Telomerase activators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Wounds
Most Recent Events
- 12 Mar 2010 Preclinical development is ongoing in USA
- 29 Jul 2003 This programme is still in active development
- 19 Jun 2001 Preclinical development for Wounds in USA (Unknown route)